Mettler-Toledo International Inc. (0K10.L)
USD 1248.03
(-0.62%)
USD 1248.03
(-0.62%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.5 Billion USD | 1.09% |
| 2022 | 3.46 Billion USD | 9.9% |
| 2021 | 3.15 Billion USD | 24.63% |
| 2020 | 2.53 Billion USD | 6.9% |
| 2019 | 2.36 Billion USD | 16.75% |
| 2018 | 2.02 Billion USD | 1.31% |
| 2017 | 2 Billion USD | 15.63% |
| 2016 | 1.73 Billion USD | 25.6% |
| 2015 | 1.37 Billion USD | 6.93% |
| 2014 | 1.28 Billion USD | 5.89% |
| 2013 | 1.21 Billion USD | 1.9% |
| 2012 | 1.19 Billion USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 3.44 Billion USD | -1.82% |
| 2024 Q2 | 3.4 Billion USD | -1.16% |
| 2023 FY | 3.5 Billion USD | 1.09% |
| 2023 Q4 | 3.5 Billion USD | 3.27% |
| 2023 Q1 | 3.43 Billion USD | -0.96% |
| 2023 Q2 | 3.46 Billion USD | 0.75% |
| 2023 Q3 | 3.39 Billion USD | -1.89% |
| 2022 Q1 | 3.27 Billion USD | 3.68% |
| 2022 Q4 | 3.46 Billion USD | 2.67% |
| 2022 FY | 3.46 Billion USD | 9.9% |
| 2022 Q2 | 3.32 Billion USD | 1.76% |
| 2022 Q3 | 3.37 Billion USD | 1.44% |
| 2021 Q3 | 3.04 Billion USD | 3.27% |
| 2021 FY | 3.15 Billion USD | 24.63% |
| 2021 Q1 | 2.82 Billion USD | 11.61% |
| 2021 Q2 | 2.95 Billion USD | 4.45% |
| 2021 Q4 | 3.15 Billion USD | 3.52% |
| 2020 Q3 | 2.32 Billion USD | 4.21% |
| 2020 Q2 | 2.22 Billion USD | -13.56% |
| 2020 Q1 | 2.57 Billion USD | 8.9% |
| 2020 FY | 2.53 Billion USD | 6.9% |
| 2020 Q4 | 2.53 Billion USD | 8.97% |
| 2019 FY | 2.36 Billion USD | 16.75% |
| 2019 Q4 | 2.36 Billion USD | 7.78% |
| 2019 Q3 | 2.19 Billion USD | 1.89% |
| 2019 Q2 | 2.15 Billion USD | 3.94% |
| 2019 Q1 | 2.07 Billion USD | 2.28% |
| 2018 Q2 | 2.02 Billion USD | 3.82% |
| 2018 Q1 | 1.95 Billion USD | -2.57% |
| 2018 FY | 2.02 Billion USD | 1.31% |
| 2018 Q4 | 2.02 Billion USD | 0.13% |
| 2018 Q3 | 2.02 Billion USD | 0.01% |
| 2017 Q2 | 1.78 Billion USD | 1.25% |
| 2017 Q4 | 2 Billion USD | 0.92% |
| 2017 FY | 2 Billion USD | 15.63% |
| 2017 Q1 | 1.76 Billion USD | 1.85% |
| 2017 Q3 | 1.98 Billion USD | 11.1% |
| 2016 FY | 1.73 Billion USD | 25.6% |
| 2016 Q3 | 1.72 Billion USD | 9.6% |
| 2016 Q1 | 1.49 Billion USD | 8.2% |
| 2016 Q4 | 1.73 Billion USD | 0.66% |
| 2016 Q2 | 1.56 Billion USD | 5.22% |
| 2015 Q3 | 1.46 Billion USD | 1.7% |
| 2015 FY | 1.37 Billion USD | 6.93% |
| 2015 Q4 | 1.37 Billion USD | -6.02% |
| 2015 Q2 | 1.44 Billion USD | 10.17% |
| 2015 Q1 | 1.3 Billion USD | 1.55% |
| 2014 Q1 | 1.21 Billion USD | -0.51% |
| 2014 Q2 | 1.23 Billion USD | 2.0% |
| 2014 Q3 | 1.25 Billion USD | 1.85% |
| 2014 Q4 | 1.28 Billion USD | 2.46% |
| 2014 FY | 1.28 Billion USD | 5.89% |
| 2013 Q4 | 1.21 Billion USD | -6.06% |
| 2013 Q2 | 1.32 Billion USD | 4.09% |
| 2013 Q3 | 1.29 Billion USD | -1.96% |
| 2013 Q1 | 1.27 Billion USD | 6.3% |
| 2013 FY | 1.21 Billion USD | 1.9% |
| 2012 FY | 1.19 Billion USD | 0.0% |
| 2012 Q4 | 1.19 Billion USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Editas Medicine, Inc. | 150.05 Million USD | -2236.123% |
| Dynavax Technologies Corporation | 375.02 Million USD | -834.738% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -619.133% |
| Perrigo Company plc | 6.04 Billion USD | 41.974% |
| Illumina, Inc. | 4.36 Billion USD | 19.709% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 93.244% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -1690.911% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 94.909% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 82.957% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -1266.776% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 50.676% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -9300.121% |
| Waters Corporation | 3.47 Billion USD | -0.834% |
| Biogen Inc. | 12.04 Billion USD | 70.898% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -4152.536% |
| Evolus, Inc. | 209.68 Million USD | -1571.774% |
| Adicet Bio, Inc. | 37.12 Million USD | -9343.677% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -4998.232% |
| bluebird bio, Inc. | 424.62 Million USD | -725.552% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -430.5% |
| FibroGen, Inc. | 585.72 Million USD | -498.485% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 28.721% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -9865.266% |
| Homology Medicines, Inc. | 118.53 Million USD | -2857.398% |
| Geron Corporation | 146.12 Million USD | -2298.936% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 13.456% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -467.502% |
| Myriad Genetics, Inc. | 312.9 Million USD | -1020.324% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -17365.463% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -1297.68% |
| Zoetis Inc. | 9.29 Billion USD | 62.286% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -7028.463% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | -85.471% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 31.93% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -7136.026% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | -34.651% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -1224.152% |
| Verastem, Inc. | 71.18 Million USD | -4824.483% |
| Nektar Therapeutics | 267.04 Million USD | -1212.693% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -782.42% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -8614.496% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | -45.744% |
| OPKO Health, Inc. | 622.47 Million USD | -463.15% |
| Exelixis, Inc. | 678.44 Million USD | -416.695% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | -243.878% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -2953.246% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -27867.871% |
| uniQure N.V. | 624.01 Million USD | -461.761% |
| Imunon, Inc. | 8.53 Million USD | -40993.992% |
| Blueprint Medicines Corporation | 918.64 Million USD | -281.596% |
| Insmed Incorporated | 1.66 Billion USD | -110.951% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | -112.523% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -2679.953% |
| TG Therapeutics, Inc. | 169.08 Million USD | -1973.213% |
| Incyte Corporation | 1.59 Billion USD | -120.157% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -195.672% |